# US 2008/0187520 A1 · Tool for the transfer and production of proteins using the pseudomonas type III secretion system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187520 A1
- Document ID: US20080187520A1
- Status: Published application
- Kind: A1
- Application number: 11/433,391
- Filed: 2006-05-12
- Published: 2008-08-07
- Earliest claimed: 2003-11-13
- Assignees: Universite Joseph Fourier
- Inventors: Benoit Polack; Bertrand Toussaint; Lauriane Quenee
- Web page: https://patentgrep.com/patent/US20080187520A1

## CPC

- C12N 15/78: for Pseudomonas
- C07K 14/21: from Pseudomonadaceae (F)
- C07K 2319/02: containing a signal sequence
- C07K 2319/036: targeting to the medium outside of the cell, e.g. type III secretion
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides a vector for expression of a chimeric protein which is the result of the fusion between the N-terminal end of ExoS of Pseudomonas aeruginosa and an amino acid sequence of interest, the N-terminal end of ExoS corresponding to the N-terminal end of the chimeric protein. The vector contains the following from 5′ to 3′: a promoter, a nucleic acid comprising a nucleotide sequence encoding at least the 48 (SEQ ID 4) and at the most the 96 (SEQ ID 6) amino acids of the N-terminal end of ExoS; or any sequence of the same size that is at least 70% identical thereto and that has a secretion activity at the same level as that of ExoS, a nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of interest.

## Claims

### Claim 1

A vector for expression of a chimeric protein whose N-terminal end corresponds to the fusion between the N-terminal end of ExoS of Pseudomonas aeruginosa and an amino acid sequence of interest, the N-terminal end of ExoS corresponding to the N-terminal end of the chimeric protein, said vector comprising the following from 5′ to 3′:
a promoter,
a nucleic acid comprising a nucleotide sequence encoding at least the 48 (SEQ ID 4) and at the most the 96 (SEQ ID 6) amino acids of the N-terminal end of ExoS, or any protein comprising a sequence of the same size, that is at least 70% identical thereto and that has a secretion activity at the same level as that of ExoS,
a nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of interest.

### Claim 2 (depends on 1)

The vector of claim 1, wherein the nucleic acid encodes the first 54 amino acids of the N-terminal end of ExoS (SEQ ID 5).

### Claim 3 (depends on 1)

The vector of claim 1, wherein the amino acid sequence of interest is an antigenic sequence.

### Claim 4

A cloning vector comprising from 5′ to 3′:
a promoter,
a nucleic acid comprising a nucleotide sequence encoding at least the 48 (SEQ ID 4) and at the most the 96 (SEQ ID 6) amino acids of the N-terminal end of ExoS, or any sequence of the same size, that is at least 70% identical thereto and that has a secretion activity at the same level as that of ExoS.

### Claim 5 (depends on 4)

The cloning vector of claim 4, wherein the nucleic acid encodes the first 54 (SEQ ID 5) amino acids of the N-terminal end of ExoS.

### Claim 6

A chimeric protein whose N-terminal end comprises at least the 48 (SEQ ID 4) and at the most the 96 (SEQ ID 6) amino acids of the N-terminal end of ExoS of P. aeruginosa or any sequence of the same size, that is at least 70% identical thereto and that has a secretion activity at the same level as that of ExoS.

### Claim 7 (depends on 6)

The chimeric protein of claim 6, wherein the N-terminal end of said chimeric protein comprises the first 54 (SEQ ID 5) amino acids of the N-terminal end of ExoS of P. aeruginosa.

### Claim 8 (depends on 6)

A gene encoding the chimeric protein of claim 6.

### Claim 9 (depends on 1)

An isolated strain of Pseudomonas aeruginosa transformed with the expression vector of claim 1.

### Claim 10 (depends on 9)

The strain of claim 9, wherein the strain is modified by deletion or mutation of at least one gene selected from the genes encoding the ExoS, ExoT, ExoU and ExoY proteins.

### Claim 11 (depends on 9)

The strain of claim 9, wherein the strain has been deposited at CNCM (Institut Pasteur de Paris) under the number I-3090.

### Claim 12 (depends on 9)

A procedure for ex vivo or in vitro injection of a chimeric protein into a eukaryotic cell comprising bringing into contact the strain of claim 9 with the eukaryotic cell.

### Claim 13 (depends on 9)

A procedure for in vivo injection of a chimeric protein into a eukaryotic cell comprising the injection of the strain of claim 9 into a living organism.

### Claim 14 (depends on 12)

The procedure according to claim 12, wherein the eukaryotic cell is an antigen presenting cell (APC).

### Claim 15 (depends on 9)

An APC-loading procedure comprising bringing into contact a strain according to claim 9 with antigen presenting cells.

### Claim 16 (depends on 9)

A procedure for producing a chimeric protein said procedure comprising the steps:
cultivate a strain according to claim 9;
induce secretion of the chimeric protein; and
recover the culture supernatant.

### Claim 17 (depends on 14)

A method for stimulating the immune system of a mammal comprising introducing antigens into APC of said mammal according to the procedure of claim 14.

### Claim 18 (depends on 14)

A method for vaccinating a mammal comprising introducing antigens into APC of said mammal according to the procedure of claim 14.

### Claim 19 (depends on 14)

A method for treating a mammal comprising introducing antigens into APC of said mammal according to the procedure of claim 14.
